Payment overview · 2025
General Payments
$38.38
2 reported records · 2 companies
Healthcare provider profile · identity verified
Tracy Marsh Carlson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALBUQUERQUE, NM · NPI 1649512542
Verified facts
What the public records show
CMS Open Payments records show Tracy Marsh Carlson, M.D. received $38.38 in general payments during 2025 across 2 reported records.
Gilead Sciences, Inc. accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Pifeltro.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 438 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Pifeltro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.67 | 53.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.71 | 46.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.38 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $17.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
438 | 51 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
320 | 34 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 438 | 51 |
| Tivicay | Dolutegravir Sodium | 395 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 46 |
| Descovy | Emtricitabine/Tenofov Alafenam | 320 | 34 |
| Lisinopril | Lisinopril | 314 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 28 |
| Gabapentin | Gabapentin | 205 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 30 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 165 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 17 |
| Losartan Potassium | Losartan Potassium | 141 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 14 |
| Finasteride | Finasteride | 132 | 17 |
| Omeprazole | Omeprazole | 131 | 19 |
| Testosterone | Testosterone | 129 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 21 |
| Famotidine | Famotidine | 113 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 101 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 11 |
| Acyclovir | Acyclovir | 89 | 14 |
| Jardiance | Empagliflozin | 81 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 77 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | suppressed |
| Allopurinol | Allopurinol | 71 | 11 |
| Ibuprofen | Ibuprofen | 68 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 62 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 62 | 11 |
| Prezcobix | Darunavir/Cobicistat | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Pregabalin | Pregabalin | 58 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 18 |
| Metformin Hcl | Metformin Hcl | 56 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Ozempic | Semaglutide | 53 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 50 | 50 |
| Juluca | Dolutegravir/Rilpivirine | 49 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Furosemide | Furosemide | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 13 |
| Fluconazole | Fluconazole | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Ritonavir | Ritonavir | 36 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Isentress | Raltegravir Potassium | 33 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Darunavir | Darunavir | 30 | suppressed |
| Pifeltro | Doravirine | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Eliquis | Apixaban | 25 | suppressed |
| Maraviroc | Maraviroc | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | suppressed |
| Etravirine | Etravirine | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Isoniazid | Isoniazid | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Abacavir | Abacavir Sulfate | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clonidine Hcl Er | Clonidine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Isentress Hd | Raltegravir Potassium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.38 · 2 records | Gilead Sciences, Inc. | PIFELTRO | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Pifeltro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error